

Webinar: The Use and Development of DHTs with Patient Advocacy Groups

The graphic features a dark blue background with a faint, repeating pattern of people silhouettes and circuit-like lines. In the top left, the Critical Path Institute logo is shown next to the text 'RARE AND ORPHAN DISEASE PROGRAMS' and 'CRITICAL PATH INSTITUTE'. To its right is the 'RDCA-DAP' logo with the subtitle 'Rare Disease Cures Accelerator Data and Analytics Platform'. The words 'WEBINAR SERIES' are prominently displayed in large, white, bold letters. On the right side, a bright yellow rounded rectangle contains the text 'Thurs | May 23 10 AM ET' and 'REGISTER NOW' in blue, with a white cursor icon pointing at the 'REGISTER NOW' text. In the lower-left foreground, a man with short brown hair, wearing a light blue button-down shirt, stands with his arms crossed. To his right, the title 'The Use and Development of DHTs with Patient Advocacy Groups' is written in large, bold, yellow letters. At the bottom, a solid blue horizontal bar contains the speaker's name and affiliations in white text.

**RARE AND ORPHAN
DISEASE PROGRAMS**
CRITICAL PATH INSTITUTE

RDCA-DAP®
Rare Disease Cures Accelerator
Data and Analytics Platform

WEBINAR SERIES

**Thurs | May 23
10 AM ET**

**REGISTER
NOW**

**The Use and
Development of
DHTs with Patient
Advocacy Groups**

Laurent Servais, MD, PhD
University of Oxford, UK,
University of Liège, Belgium

On Thursday, May 23, C-Path was joined by Dr. [Laurent Servais](#) of the University of Oxford and the University of Liège, for an overview of Actimyo and relevant learnings from use cases across rare disorders spanning different degrees of complexity and readiness. Additionally, patient advocacy group leaders will speak to their experience based on stage of development and the ability of Actimyo to assess individuals with a neuromuscular disorder or non-NMDs (e.g., Duchenne muscular dystrophy, Angelman syndrome, and CTNNB1).

View the webinar recording below: